Bevacizumab tachyphylaxis.
Khalil Ghasemi
KG
Falavarjani
Mehdi
M
Modarres
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005122:Exudates and Transudates; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D012160:Retina / Q000473:pathology; D019233:Retreatment; D012189:Retrospective Studies; D013618:Tachyphylaxis; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide